Literature DB >> 30968632

Effects of Lactobacillus rhamnosus GG as a probiotic on neonatal hyperbilirubinemia.

Mehmet Mutlu1, Erdal Irmak2, Yakup Aslan1, Şebnem Kader1.   

Abstract

Mutlu M, Irmak E, Aslan Y, Kader Ş. Effects of Lactobacillus rhamnosus GG as a probiotic on neonatal hyperbilirubinemia. Turk J Pediatr 2018; 60: 482-487. Undeveloped intestinal microflora and increased enterohepatic circulation of the newborn contribute to increase of plasma bilirubin level in the first days of life. This study was undertaken to determine the role of probiotic support started immediately after birth on neonatal hyperbilirubinemia in babies born by normal spontaneous vaginal delivery and breastfed only. A total of 150 healthy term newborns were included in the study and allocated in the study and control groups. Immediately after birth, newborns in the study group received probiotic in liquid drop form (Maflor® drops containing Lactobacillus Rhamnosus GG 109 colony forming units, Mamsel Ilac, Turkey), at a dose of 5 drops a day, orally for 10 days. Newborns in the control group received 5 drops of saline solution per day orally, instead. Serum bilirubin levels (cord, 3rd, 5th and 10th days of life) and defecation frequency were recorded. Mean total bilirubin levels on the 3rd, 5th and 10th days were significantly lower and mean defecation frequency was significantly higher in the probiotic group compared to the controls (p < 0.05 for each). Negative correlations were determined between defecation frequency and the 3rd, 5th and 10th day-total bilirubin levels (r=-0.804, p < 0.001; r=-0.818, p < 0.001; r=-0.648, p < 0.001, respectively). Probiotic (Lactobacillus rhamnosus GG) support initiated immediately after birth has a positive effect on bilirubin metabolism and may reduce the risk of hyperbilirubinemia.

Entities:  

Keywords:  hyperbilirubinemia; meconium; newborn; probiotic

Mesh:

Substances:

Year:  2018        PMID: 30968632     DOI: 10.24953/turkjped.2018.05.003

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  2 in total

1.  Short-Term Tolerability, Safety, and Gut Microbial Composition Responses to a Multi-Strain Probiotic Supplement: An Open-Label Study in Healthy Adults.

Authors:  Jennifer Joan Ryan; Noelle M Patno
Journal:  Integr Med (Encinitas)       Date:  2021-02

2.  Clinical Manifestations of Neonatal Hyperbilirubinemia Are Related to Alterations in the Gut Microbiota.

Authors:  Xueli Zhang; Shujuan Zeng; Guoqiang Cheng; Liufang He; Mingqiu Chen; Mingbang Wang; Wenhao Zhou; Huixian Qiu; Zhangxing Wang
Journal:  Children (Basel)       Date:  2022-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.